AVBP Earnings Arrivent Biopharma, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–13 of 13
| Q1 2026 | 2026-03-31 | -0.96 | 2026-05-11 | 10-Q |
| FY 2025 | 2025-12-31 | -4.32 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -3.54 | 2025-11-10 | 10-Q |
| Q2 2025 | 2025-06-30 | -2.78 | 2025-08-11 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.90 | 2026-05-11 | 10-Q |
| FY 2025 | 2024-12-31 | -2.56 | 2026-03-05 | 10-K |
| Q3 2025 | 2024-09-30 | -1.95 | 2025-11-10 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.34 | 2025-08-11 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.70 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -32.38 | 2025-03-03 | 10-K |
| Q3 2024 | 2023-09-30 | -24.69 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -20.60 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -9.45 | 2024-05-08 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.